Healthy Skepticism Library item: 11188
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Chadwick D, Marson T.
Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients.
Epilepsia 2007 Jul; 48:(7):1259-63
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1528-1167.2007.01086.x
Abstract:
The ILAE treatment guidelines for initial monotherapy emphasise the poor quality of information available to inform everyday clinical practice. Industry sponsored studies comparing antiepileptic drugs answer restricted licensing questions, rather than those relevant to the clinical community (patients, health professionals and founders of health care). The SANAD study, a pragmatic randomized clinical trial, offers a methodology to address some of these questions. It identifies lamotrigine as a cost-effective alternative to carbamazepine for the treatment of focal epilepsies, but confirms valproate as the most effective drug for the treatment of generalized or unclassified epilepsy.
Keywords:
MeSH Terms:
Anticonvulsants/economics
Anticonvulsants/therapeutic use*
Carbamazepine/economics
Carbamazepine/therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Industry/economics
Drug Industry/statistics & numerical data
Epilepsies, Partial/drug therapy
Epilepsy/drug therapy*
Epilepsy, Generalized/drug therapy
Humans
Practice Guidelines
Randomized Controlled Trials/economics
Randomized Controlled Trials/statistics & numerical data
Research Support/economics
Treatment Outcome
Triazines/economics
Triazines/therapeutic use
Substances:
Anticonvulsants
Triazines
Carbamazepine
lamotrigine
